Sepracor Reports Promising Phase III Data For Epilepsy Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Late 2008/early 2009 NDA filing is targeted for eslicarbazepine as adjunct therapy for epileptic seizure control.